Program Overview
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small peptidomimetic compound. ShiLai™ Healthcare's oral Dihexa program focuses on formulation development, dosage-form engineering, and stability evaluation for oral delivery formats.
This program is positioned as a research and development formulation engagement. No therapeutic, clinical, or efficacy claims are made. Commercial availability and regulatory status are subject to the specific program scope agreed with each B2B partner.
Formulation Development
Oral Dihexa formulation development at ShiLai™ Healthcare follows the structured workflow of the Oral Peptide Delivery Platform:
Pre-Formulation Assessment
Physicochemical characterisation of Dihexa to inform dosage-form selection and excipient strategy.
Excipient Screening
Evaluation of excipients for compatibility with Dihexa under formulation and storage conditions.
Dosage-Form Development
Development of prototype oral dosage forms based on pre-formulation findings and program requirements.
Stability Evaluation
Stability studies under defined conditions to assess chemical and physical stability, moisture sensitivity, and shelf-life potential.
Analytical Verification
Analytical verification throughout the oral Dihexa program applies HPLC and LC-MS methods for identity, purity, and content determination. Stability samples are monitored analytically to track formulation integrity. Batch documentation and COA are provided for each manufacturing batch.
OEM & CDMO Development
B2B partners can engage ShiLai™ Healthcare for oral Dihexa formulation development, scale-up, and OEM/CDMO manufacturing. Engagements are structured around the partner's program scope and documentation requirements.
B2B only. Research formulation program. No retail or individual orders. No therapeutic or clinical claims.
Discuss an Oral Peptide Project